David Fuller

Mr Fuller is a biopharmaceutical executive and has experience of developing and commercialising new products in international environments. He has led five product approvals in the United States (US) and European Union (EU) for orphan and major market products, together with multiple Regulatory Agency (US/EU) interactions including Investigational New Drug (IND) applications. David has designed and executed multiple Phase I - III studies in US, EU and Asia across multiple therapeutic areas. His development experience encompasses pre-clinical, clinical development, medical and regulatory affairs with a specialisation in the early phase development of biological molecules. David is currently Senior Vice President, Clinical Development, Oncology Business Unit, Syneos Health where he has overall responsibility for the strategy and growth of the Oncology Business Unit in Asia Pacific. He is also a Non-Executive Director at EpiAxis Therapeutics Pty Ltd as well as Linear Clinical Research Ltd, a Perth based clinical trials facility and is a former Chair of Dimerix Ltd (ASX:DXB).